OOIR: Observatory of International Research

Papers

(The H4-Index of Multiple Sclerosis Journal is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-12-01 to 2024-12-01.)

Article	Citations
COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021	185
A smartphone sensor-based digital outcome assessment of multiple sclerosis	68
Relationship between paramagnetic rim lesions and slowly expanding lesions in multiple sclerosis	47
Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres	46
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study	45
Which exercise and behavioural interventions show most promise for treating fatigue in multiple sclerosis? A network meta-analysis	45
Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension	41
Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network	41
Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II	41
Cortical lesion hotspots and association of subpial lesions with disability in multiple sclerosis	40
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years	39
Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results	39
MSVirtual 2020 – Poster Abstracts	38
Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4–immunoglobulin G–seropositive participants taking inebilizumab for ⩾4 years in the N-MO	37
Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic	36
Childhood obesity and multiple sclerosis: A Mendelian randomization study	35
Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies	35
A randomized study of natalizumab dosing regimens for relapsing–remitting multiple sclerosis	35
Cognitive impairment, the central vein sign, and paramagnetic rim lesions in RIS	34
Optical coherence tomography angiography indicates subclinical retinal disease in neuromyelitis optica spectrum disorders	33
Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis	33
Serum neurofilament light in MS: The first true blood-based biomarker?	33
Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis	32
The relative contributions of obesity, vitamin D, leptin, and adiponectin to multiple sclerosis risk: A Mendelian randomization mediation analysis	32
Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology	32

The timed 25-foot walk in a large cohort of multiple sclerosis patients	32
ADEM after ChAdOx1 nCoV-19 vaccine: A case report	31
Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis	31
Lesion-level correspondence and longitudinal properties of paramagnetic rim and slowly expanding lesions in multiple sclerosis	31
Mediterranean diet is linked to less objective disability in multiple sclerosis	29
Serum ceramide levels are altered in multiple sclerosis	29
Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis	29